0001641172-25-010277 | 10-Q | XBRL Viewer

Gross proceeds from cash fee percentage

3.00%

7.00%

Gross proceeds from management fee percentage

1.00%

Stock issued during period, value, new issues

$ 25,917

^[1]

$ 2,397

^[2]

Litigation settlement amount

$ 2,154

Liabilities current

$ 1,893

1,893

$ 2,460

Assets current

30,656

$ 5,819

Settlement amount recovery

$ 1,100

Legal expense

235

Non operating loss on legal settlement

1,111

Proceeds from Legal Settlements

316

CEO, Executives [Member]

Certain Employees [Member]

Accrued bonuses

176

Accrued bonuses

176

Device [Member]

Integrated Product [Member]

Royalties percentage

3.00%

Royalties percentage

1.50%

Common Stock [Member]

Stock issued during period, value, new issues

$ 139

^[1]

$ 17

^[2]

At-the-Market Offering Agreement [Member] | Common Stock [Member]

13,891,840

^[1]

1,685,682

^[2]

Percentage of placement fee

Aggregate offering

$ 4,820

3.00%

Securities Purchase Agreement [Member]

842,606

3,433,880

Purchase price of plaintiffs

$ 6,750

Securities Purchase Agreement [Member] | Common Stock [Member]

Litigation Settlement [Member]

6,103,289

3,788,550

4,000,001

Payment for litigation settlement

$ 1,100

Restricted common shares issued for legal settlement | shares

1,005,965

Liabilities current

2,211

Assets current

1,335

Insurance recovery amount

$ 1,335

Litigation Settlement [Member] | Common Stock [Member]

Israeli Innovation Authority [Member]

1,005,965

Additional grant receivable

Grants receivable

$ 378

378

$ 83

₪ 300,000

$ 447

₪ 1,620,000

Israeli Innovation Authority [Member] | Minimum [Member]

Israeli Innovation Authority [Member] | Maximum [Member]

3.00%

Israeli Innovation Authority [Member] | CardioSert Ltd [Member]

5.00%

Repayment of government grants

$ 925

Ministry of Economy [Member]

Technion Research and Development Foundation Limited [Member] | Minimum [Member]

Grants receivable

$ 50

Technion Research and Development Foundation Limited [Member] | Maximum [Member]

1.50%

H.C. Wainwright & Co. LLC [Member]

3.00%

Warrant issued, descriptions

The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. See also Note 4B below

H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]

Stock issued during period, value, new issues

Offering costs

$ 10,000

$ 8,000

2013 Through March 31, 2025 [Member] | Israeli Innovation Authority [Member]

Balances at Dec. 31, 2023

Revenue grants received

$ 1,878

[1]	Net of issuance costs in the amount of $2,683, of which $10 had not been paid as of March 31, 2025.
[2]	Net of issuance costs in the amount of $333.

Interim Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Total

$ 118

$ 83,884

$ (79,501)

$ 4,501

Balance, shares at Dec. 31, 2023

11,707,317

Issuance of common stock and warrants net of issuance costs

^[1]

$ 17

2,380

2,397

Issuance of common stock and warrants net of issuance costs, shares

^[1]

1,685,682

Issuance of common stock relating to settlement agreement

^[2]

$ 10

1,101

1,111

Issuance of common stock relating to settlement agreement, shares

^[2]

1,005,965

529

Balances at Mar. 31, 2024

(2,371)

$ 145

87,894

(81,872)

6,167

Balances, shares at Mar. 31, 2024

14,398,964

Balances at Dec. 31, 2023

$ 118

83,884

(79,501)

4,501

Balance, shares at Dec. 31, 2023

11,707,317

Balances at Dec. 31, 2024

$ 195

94,279

(90,944)

3,530

Balances, shares at Dec. 31, 2024

19,399,513

Issuance of common stock and warrants net of issuance costs

^[3]

$ 139

25,778

25,917

Issuance of common stock and warrants net of issuance costs, shares

^[3]

13,891,840

256

Issuance of common stock under the at-the-market offering program

(2,601)

^[4]

$ 8

989

997

Issuance of common stock under the at-the-market offering program, shares

^[4]

842,606

Issuance of common stock upon exercise of warrants

^[5]

$ 6

846

852

Issuance of common stock upon exercise of warrants, shares

610,517

Balances at Mar. 31, 2025

$ 348

$ 122,148

$ (93,545)

$ 28,951

Balances, shares at Mar. 31, 2025

34,744,476

[1]	Net of issuance costs in the amount of $333.
[2]	See Note 3F.
[3]	Net of issuance costs in the amount of $2,683, of which $10 had not been paid as of March 31, 2025.
[4]	Net of issuance costs in the amount of $65.
[5]	Net of issuance costs in the amount of $64.

SHARE CAPITAL (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

Feb. 09, 2025

Jan. 07, 2025

Jan. 06, 2025

Jul. 01, 2024

Feb. 28, 2025

Jan. 31, 2025

Feb. 29, 2024

Mar. 31, 2025

Mar. 31, 2024

Dec. 31, 2024

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock, par value

$ 0.01

Issuance costs

$ 2,683

$ 333

Chief Executive Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

$ 1.25

Chief Executive Officer and Other Executives [Member]

79,567

228,000

Compensation percentage

25.00%

Annual bonus

$ 99

Accumulated Other Comprehensive Income (Loss) [Line Items]

35,625

$ 1.25

Accumulated Other Comprehensive Income (Loss) [Line Items]

132,500

Compensation expenses

$ 38

CEO, Executives [Member]

$ 1.2684

Certain Employees [Member]

80,000

Accumulated Other Comprehensive Income (Loss) [Line Items]

$ 1.2684

Accumulated Other Comprehensive Income (Loss) [Line Items]

115,000

Advisors [Member]

$ 0.881

Accumulated Other Comprehensive Income (Loss) [Line Items]

25,000

Executives [Member]

Certain Employees and Certain Board Members [Member]

313,875

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accumulated Other Comprehensive Income (Loss) [Line Items]

70,000

Board [Member]

Number of options forfeited

35,625

Number of options vested

132,500

96,875

Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Issuance costs

$ 64

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common Stock [Member] | Chief Executive Officer [Member]

13,891,840

^[1]

1,685,682

^[2]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Additional number of stock options granted

80,000

80,000

Common Stock [Member] | Management [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted-average exercise price per share, granted

50,000

$ 1.2684

Additional number of stock options granted

52,500

Common Stock [Member] | Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Placement agent fee

$ 13,000

$ 8,600

$ 7,000

Offering expense

$ 1,176

$ 818

$ 690

Common Stock [Member] | Series G Preferred Investment Options [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

8,000,002

Common Stock [Member] | Series H Preferred Investment Options [Member]

$ 1.75

Accumulated Other Comprehensive Income (Loss) [Line Items]

7,577,100

Common Stock [Member] | Series I Preferred Investment Options [Member]

$ 2.10

Accumulated Other Comprehensive Income (Loss) [Line Items]

12,206,578

Securities Purchase Agreement [Member] | Common Stock [Member]

$ 2.13

Accumulated Other Comprehensive Income (Loss) [Line Items]

6,103,289

3,788,550

4,000,001

Common stock, par value

$ 0.01

H.C. Wainwright & Co. LLC [Member] | Common Stock [Member]

$ 2.13

$ 2.27

$ 1.75

Accumulated Other Comprehensive Income (Loss) [Line Items]

305,164

189,428

200,000

At-the-Market Offering Agreement [Member]

$ 2.6625

$ 2.8375

$ 2.1875

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other offering expenses

$ 65

$ 239

At-the-Market Offering Agreement [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of Stock, Consideration Received on Transaction

842,606

3,433,880

$ 4,820

Total gross proceeds

$ 1,062

$ 3,756

Exercise Of Investment Options [Member] | Series E Preferred Investment Options [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Value, Stock Options Exercised

$ 916

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period

610,517

[1]	Net of issuance costs in the amount of $2,683, of which $10 had not been paid as of March 31, 2025.
[2]	Net of issuance costs in the amount of $333.

GENERAL

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1 – GENERAL

A. Description of business

Microbot Medical Inc. (the “Company”) is a pre-commercial, clinical-stage medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.

The Company incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.

On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”.

The Company and Microbot Israel, its sole subsidiary, are sometimes collectively referred to as the “Company” as the context may require.

B. Risk Factors

To date, the Company has not generated revenues from its operations. As of March 31, 2025, the Company had cash equivalents and marketable securities balance of approximately $30,390, excluding restricted cash. Due to continuing research and development and pre-commercialization activities, the Company expects to continue to incur additional losses for the foreseeable future. Notwithstanding these conditions, the Company’s management has concluded that the available funds as of the balance sheet date, combined with the capital raises completed as described in Note 6, are sufficient to fund the Company’s operations for more than twelve months from the issuance date of these financial statements.

The Company expects to raise additional funds through future issuances of either debt and/or equity securities, including upon the cash exercise of outstanding investment options, and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.

Israel-Hamas War

On October 7, 2023, the State of Israel, where our research and development and other operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza and then in Lebanon. These military operations and related activities, such as the recent collapse of the Assad regime in Syria and Israel’s subsequent military operations in Syria, and the recent escalation of military operations by and against the Houthis in Yemen, are on-going as of the issuance date of these financial statements, although there have been temporary cease fires from time to time.

The Company has considered various ongoing risks relating to the military operations and related matters, including:

●

That some of our Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; and

●

A slowdown in the number of international flights in and out of Israel.

The Company is closely monitoring how the military operations and related activities could adversely affect our anticipated milestones and our Israel-based activities to support future clinical and regulatory milestones, including our ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the issuance date of these financial statements, the Company has determined that there have not been any materially adverse effects on its business or operations, but the Company continues to monitor the situation, as any collapse of a cease-fire with Hamas or Hezbollah that may be in effect from time to time, or any further or future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support its clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change.

C. Unaudited Interim Financial Statements

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). These interim consolidated condensed financial statements should be read in conjunction with the Company’s latest audited financial statements.

Operating results for the three-month period ended March 31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.

SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2025

Mar. 31, 2024

Segment Reporting Information [Line Items]

$ (256)

$ (453)

Other Operating Segment [Member]

(2,601)

(2,371)

Segment Reporting Information [Line Items]

Payroll and payroll related

1,548

1,067

Materials and subcontractors

278

264

256

454

Other segment items

^[1]

519

586

$ 2,601

$ 2,371

[1]

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

SHARE CAPITAL

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

SHARE CAPITAL

NOTE 4 - SHARE CAPITAL

A. Registered direct and private placement offerings

On January 6, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of 4,000,001 shares of the Company’s common stock, par value $0.01 per share, at an offering price of $1.75 per share, for aggregate gross proceeds from the offerings of approximately $7,000 before deducting the placement agent fee and related offering expenses of approximately $690. In a concurrent private placement, the Company agreed to issue to the investors series G preferred investment options to purchase up to 8,000,002 shares of common stock at an exercise price of $1.75 per share. Each Series G preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to 200,000 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $2.1875 per share.

On January 7, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of 3,788,550 shares of the Company’s common stock, par value $0.01 per share, at an offering price of $2.27 per share, for aggregate gross proceeds from the offerings of approximately $8,600 before deducting the placement agent fee and related offering expenses of approximately $818. In a concurrent private placement, the Company agreed to issue to the investors series H preferred investment options to purchase up to 7,577,100 shares of common stock at an exercise price of $2.10 per share. Each Series H preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to 189,428 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $2.8375 per share.

On February 9, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of 6,103,289 shares of the Company’s common stock, par value $0.01 per share, at an offering price of $2.13 per share, for aggregate gross proceeds from the offerings of approximately $13,000 before deducting the placement agent fee and related offering expenses of approximately $1,176. In a concurrent private placement, the Company agreed to issue to the investors series I preferred investment options to purchase up to 12,206,578 shares of common stock at an exercise price of $2.13 per share. Each Series I preferred investment option is exercisable on the later of (i) the date on which the amendment to the Company’s articles of incorporation that increases the number of authorized shares of common stock to an amount of shares of common stock sufficient for the exercise in full of the series I preferred investment options is filed and accepted with the State of Delaware law (such date, the “Authorized Share Increase Date”) and

(ii) the date on which approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to the issuance of all the series I preferred investment options and the shares of common stock issuable upon the exercise thereof, is received and deemed effective under Delaware law (the “Initial exercise date”), and will expire two years from the initial exercise date. Net cash settlements are not permitted under any event under the Securities Purchase Agreements.

The Company also issued to Wainwright or its designees preferred investment options to purchase up to 305,164 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $2.6625 per share.

B. At-the-market offerings

On July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $4,820 of the Company’s shares of common stock pursuant to the ATM Agreement. During the year 2024, the Company issued 3,433,880 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $3,756 before deducting sales agent commissions and other offering expenses of $239.

In January 2025, the Company issued 842,606 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $1,062 before deducting sales agent commissions and other offering expenses of $65. The Company is no longer selling its securities pursuant to the ATM Agreement and has not as of the filing of these financial statements entered into a new or replacement ATM agreement.

C. Exercise of Investment Options

In January 2025, the Company raised approximately $916 in gross proceeds from the exercise of 610,517 outstanding Series E preferred investment options, before deducting placement agent fee of $64.

D. Equity classification

The common stock of the Company are recognized as equity under the requirements of ASC Topic 505 Equity.

The Company analyzed the accounting treatment for all of the outstanding preferred investment options. Based on the Company’s analysis all such warrants were classified as equity.

The Company analyzed the accounting treatment for all of the outstanding preferred investment options issued to Wainwright. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards.

E. Employee Stock Option Grants

During the year ended December 31, 2024:

●

The Company granted the CEO, its executives and management, fully vested options to purchase an aggregate of 80,000 and 50,000 shares of the Company’s common stock, respectively, at an exercise price per share of $1.2684.

●

The Company granted the CEO and certain executives, options to purchase an aggregate of 80,000 and 52,500 shares of the Company’s common stock, respectively, at an exercise price per share of $1.25. The vesting of these options is subject to the achievement of specified performance conditions. For the year ended December 31, 2024, the Company recorded an expense of $38, reflecting management’s assessment that the specified performance milestones for 35,625 of the 132,500 options were achieved by their due date.

●

The Company granted the CEO, its executives, and certain employees, options to purchase an aggregate of 80,000 and 115,000 shares of the Company’s common stock, respectively, at an exercise price per share of $1.2684, with a vesting period of three years.

●

The Company granted an advisor options to purchase an aggregate of 25,000 shares of the Company’s common stock, at an exercise price per share of $0.881, with a vesting period of three years.

With respect to the CEO’s 2023 annual bonus, during February 2024, the Company paid 25% of the CEO’s total 2023 bonus – amounting to approximately $99, through the grant of fully vested options to purchase an aggregate of 79,567 shares of the Company’s common stock with an exercise price per share of $1.25.

During the three months ended March 31, 2025, the Company granted the CEO, executives and certain employees, and certain board members, 228,000, 313,875 and 70,000 options, respectively. In addition, in February 2025, the Company determined that 35,625 out of 132,500 performance-based options granted in February 2024 had met their milestones and been vested, while the remainder 96,875 options which did not meet their milestones had been forfeited.

F. Warrants:

The remaining outstanding warrants and terms as of March 31, 2025 and December 31, 2024 are as follows:

SCHEDULE OF WARRANTS OUTSTANDING

Issuance date	Outstanding and exercisable as of March 31, 2025		Outstanding and exercisable as of December 31, 2024		Exercise Price		Exercisable Through
Warrant to underwriters October 2022		51,125		51,125	$	6.11	October 21, 2027
Warrant to underwriters May 2023		32,778		32,778	$	2.75	November 23, 2026
Warrant to underwriters May 2023		60,476		60,476	$	2.75	November 24, 2026
Warrant to underwriters June 2023		35,088		35,088	$	2.67	June 2, 2028
Warrant to underwriters June 2023		31,231		31,231	$	4.06	June 28, 2028
Warrant series E January 2024		1,075,165		1,685,682	$	1.50	July 3, 2029
Warrant to underwriters January 2024		84,284		84,284	$	2.03	July 3, 2029
Warrant series F June 2024		3,133,338		3,133,338	$	1.50	June 3, 2026
Warrant to underwriters June 2024		78,333		78,333	$	1.88	June 3, 2026
Warrant series G January 2025		8,000,002		-	$	1.75	January 7, 2027
Warrant to underwriters January 2025		200,000		-	$	2.1875	January 7, 2027
Warrant series H January 2025		7,577,100		-	$	2.10	January 10, 2027
Warrant to underwriters January 2025		189,428		-	$	2.8375	January 10, 2027
Warrant to underwriters January 2025		30,526		-	$	1.875	July 8, 2030
Warrant series I February 2025		12,206,578		-	$	2.13	(*)
Warrant to underwriters February 2025		305,164		-	$	2.6625	(*)

(*)	See Note 4A.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

SCHEDULE OF WARRANTS OUTSTANDING

Interim Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($)
Subsidiary, Sale of Stock [Line Items]
Issuance costs	$ 2,683
Stock issuance cost not paid	10
At-the-Market Offering Program [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance costs	65
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance costs	$ 64

SHARE CAPITAL (Tables)

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

The remaining outstanding warrants and terms as of March 31, 2025 and December 31, 2024 are as follows:

SCHEDULE OF WARRANTS OUTSTANDING

Issuance date	Outstanding and exercisable as of March 31, 2025		Outstanding and exercisable as of December 31, 2024		Exercise Price		Exercisable Through
Warrant to underwriters October 2022		51,125		51,125	$	6.11	October 21, 2027
Warrant to underwriters May 2023		32,778		32,778	$	2.75	November 23, 2026
Warrant to underwriters May 2023		60,476		60,476	$	2.75	November 24, 2026
Warrant to underwriters June 2023		35,088		35,088	$	2.67	June 2, 2028
Warrant to underwriters June 2023		31,231		31,231	$	4.06	June 28, 2028
Warrant series E January 2024		1,075,165		1,685,682	$	1.50	July 3, 2029
Warrant to underwriters January 2024		84,284		84,284	$	2.03	July 3, 2029
Warrant series F June 2024		3,133,338		3,133,338	$	1.50	June 3, 2026
Warrant to underwriters June 2024		78,333		78,333	$	1.88	June 3, 2026
Warrant series G January 2025		8,000,002		-	$	1.75	January 7, 2027
Warrant to underwriters January 2025		200,000		-	$	2.1875	January 7, 2027
Warrant series H January 2025		7,577,100		-	$	2.10	January 10, 2027
Warrant to underwriters January 2025		189,428		-	$	2.8375	January 10, 2027
Warrant to underwriters January 2025		30,526		-	$	1.875	July 8, 2030
Warrant series I February 2025		12,206,578		-	$	2.13	(*)
Warrant to underwriters February 2025		305,164		-	$	2.6625	(*)

(*)	See Note 4A.

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 3,217	$ 3,114
Marketable securities	27,173	2,356
Restricted cash	48	49
Prepaid expenses and other current assets	218	300
Total current assets	30,656	5,819
Property and equipment, net	78	80
Operating right-of-use assets	158	132
Total assets	30,892	6,031
Current liabilities:
Accounts payable	186	165
Lease liabilities	90	70
Accrued liabilities	1,617	2,225
Total current liabilities	1,893	2,460
Non-current liabilities:
Long-term lease liabilities	48	41
Total liabilities	1,941	2,501
Shareholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 34,744,476 and 19,399,513 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.	348	195
Additional paid-in capital	122,148	94,279
Accumulated deficit	(93,545)	(90,944)
Total shareholders’ equity	28,951	3,530
Total liabilities and shareholders’ equity	$ 30,892	$ 6,031

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities:
Net loss	$ (2,601)	$ (2,371)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation of property and equipment	15	28
Share-based compensation	256	453
Changes in assets and liabilities:
Prepaid expenses and other assets	73	(389)
Other payables and accrued liabilities	(617)	(376)
Insurance recovery related to legal settlement and legal expenses received in cash		1,335
Legal settlement paid in cash		(1,100)
Net cash flows used in operating activities	(2,874)	(2,420)
Investing activities:
Purchases of property and equipment	(13)	(14)
Purchases of marketable securities	(28,118)	(5,120)
Proceeds from sales of a marketable securities	3,301	1,350
Proceeds from maturities of marketable securities		2,500
Net cash flows used in investing activities	(24,830)	(1,284)
Financing activities:
Issuance of common stock and warrants, net of issuance costs	27,806	2,397
Net cash flows provided by financing activities	27,806	2,397
Increase (decrease) in cash, cash equivalents and restricted cash	102	(1,307)
Cash, cash equivalents and restricted cash at beginning of period	3,163	2,517
Cash, cash equivalents and restricted cash at end of period	3,265	1,210
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities	47	37
Deferred expenses offset against additional paid in capital	30
Issuance expenses not paid	10
Legal settlement settled through issuance of common stock		1,111
Accrued bonus settled through grant of stock-option awards		$ 76

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES

The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2025 and December 31, 2024:

	Total		Level 1		Level 2		Level 3
	As of March 31, 2025
	Total		Level 1		Level 2		Level 3

Marketable securities:
Money market mutual funds	$	27,173	$	27,173	$	-	$	-
Marketable securities	$	27,173	$	27,173	$	-	$	-

	Total		Level 1		Level 2		Level 3
	As of December 31, 2024
	Total		Level 1		Level 2		Level 3

Marketable securities:
Money market mutual funds	$	2,356	$	2,356	$	-	$	-
Marketable securities	$	2,356	$	2,356	$	-	$	-

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Basis of presentation:

Basis of presentation:

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Use of estimates:

Use of estimates:

Fair value of financial instruments:

Fair value of financial instruments:

The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments.

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2025 and December 31, 2024:

	Total		Level 1		Level 2		Level 3
	As of March 31, 2025
	Total		Level 1		Level 2		Level 3

Marketable securities:
Money market mutual funds	$	27,173	$	27,173	$	-	$	-
Marketable securities	$	27,173	$	27,173	$	-	$	-

	Total		Level 1		Level 2		Level 3
	As of December 31, 2024
	Total		Level 1		Level 2		Level 3

Marketable securities:
Money market mutual funds	$	2,356	$	2,356	$	-	$	-
Marketable securities	$	2,356	$	2,356	$	-	$	-

Share-based compensation:

Share-based compensation:

Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.

Recently adopted accounting pronouncements:

Recently adopted accounting pronouncements:

Accounting pronouncements not yet effective:

Accounting pronouncements not yet effective:

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.C.Q3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.1.Q5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.3.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2.Q6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/718/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Research and development, net	$ (1,459)	$ (1,169)
General and administrative	(1,562)	(1,215)
Operating loss	(3,021)	(2,384)
Other income (see Note 3G)	316
Financing income, net	104	13
Net loss	$ (2,601)	$ (2,371)
Basic net loss per share	$ (0.08)	$ (0.17)
Diluted net loss per share	$ (0.08)	$ (0.17)
Basic weighted average common shares outstanding	31,085,606	14,055,973
Diluted weighted average common shares outstanding	31,085,606	14,055,973

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (2,601)	$ (2,371)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Warrant To Underwriters October 2022 [Member]

SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares

3 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Accumulated Other Comprehensive Income (Loss) [Line Items]

51,125

$ 6.11

Warrant To Underwriters One May 2023 [Member]

October 21, 2027

Accumulated Other Comprehensive Income (Loss) [Line Items]

32,778

$ 2.75

Warrant To Underwriters Two May 2023 [Member]

November 23, 2026

Accumulated Other Comprehensive Income (Loss) [Line Items]

60,476

$ 2.75

Warrant to Underwriters One June 2023 [Member]

November 24, 2026

Accumulated Other Comprehensive Income (Loss) [Line Items]

35,088

$ 2.67

Warrant to Underwriters Two June 2023 [Member]

June 2, 2028

Accumulated Other Comprehensive Income (Loss) [Line Items]

31,231

$ 4.06

Warrant Series E January 2024 [Member]

June 28, 2028

Accumulated Other Comprehensive Income (Loss) [Line Items]

1,075,165

1,685,682

$ 1.50

Warrant to Underwriters January 2024 [Member]

July 3, 2029

Accumulated Other Comprehensive Income (Loss) [Line Items]

84,284

$ 2.03

Warrant Series F June 2024 [Member]

July 3, 2029

Accumulated Other Comprehensive Income (Loss) [Line Items]

3,133,338

$ 1.50

Warrant to Underwriters June 2024 [Member]

June 3, 2026

Accumulated Other Comprehensive Income (Loss) [Line Items]

78,333

$ 1.88

Warrant Series G January 2025 [Member]

June 3, 2026

Accumulated Other Comprehensive Income (Loss) [Line Items]

8,000,002

$ 1.75

Warrant To Underwriters January 2025 [Member]

January 7, 2027

Accumulated Other Comprehensive Income (Loss) [Line Items]

200,000

$ 2.1875

Warrant Series H January 2025 [Member]

January 7, 2027

Accumulated Other Comprehensive Income (Loss) [Line Items]

7,577,100

$ 2.10

Warrant To Underwriters January 2025 One [Member]

January 10, 2027

Accumulated Other Comprehensive Income (Loss) [Line Items]

189,428

$ 2.8375

Warrant To Underwriters January 2025 Two [Member]

January 10, 2027

Accumulated Other Comprehensive Income (Loss) [Line Items]

30,526

$ 1.875

Warrant Series I February 2025 [Member]

July 8, 2030

Accumulated Other Comprehensive Income (Loss) [Line Items]

12,206,578

$ 2.13

Warrant to Underwriters February 2025 [Member]

^[1]

(*)

Accumulated Other Comprehensive Income (Loss) [Line Items]

305,164

$ 2.6625

^[1]

(*)

[1]	See Note 4A.

SEGMENT REPORTING

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 5 – SEGMENT REPORTING

Segment information is prepared on the same basis that the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer, manages the business, makes business decisions and assesses performance. The Company has one operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details.

The CODM assesses performance for this segment and decides how to allocate resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents and marketable securities. The chief executive officer performs the assessment of segment performance by using the reported measure of segment loss to monitor actual results.

The table below summarizes the significant expense categories regularly reviewed by the CODM for the three months ended March 31, 2025 and 2024:

	2025		2024
	For the three months ended March 31,
	2025		2024
Significant segment expenses
Payroll and payroll related	$	1,548		1,067
Materials and subcontractors		278		264
Share-based compensation		256		454
Other segment items (*)		519		586
Net loss	$	2,601		2,371

(*)

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32